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Abstract
Favorable health outcomes at 2 years postbariatric surgery have been reported. With exception of
the Swedish Obesity Subjects (SOS) study, these studies have been surgical case series, comparison
of surgery types, or surgery patients compared to subjects enrolled in planned nonsurgical
intervention. This study measured gastric bypass effectiveness when compared to two separate
severely obese groups not participating in designed weight-loss intervention. Three groups of
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severely obese subjects (N = 1,156, BMI ≥ 35 kg/m2) were studied: gastric bypass subjects (n = 420),
subjects seeking gastric bypass but did not have surgery (n = 415), and population-based subjects
not seeking surgery (n = 321). Participants were studied at baseline and 2 years. Quantitative outcome
measures as well as prevalence, incidence, and resolution rates of categorical health outcome
variables were determined. All quantitative variables (BMI, blood pressure, lipids, diabetes-related
variables, resting metabolic rate (RMR), sleep apnea, and health-related quality of life) improved
significantly in the gastric bypass group compared with each comparative group (all P < 0.0001,
except for diastolic blood pressure and the short form (SF-36) health survey mental component score
at P < 0.01). Diabetes, dyslipidemia, and hypertension resolved much more frequently in the gastric
bypass group than in the comparative groups (all P < 0.001). In the surgical group, beneficial changes
of almost all quantitative variables correlated significantly with the decrease in BMI. We conclude
that Roux-en-Y gastric bypass surgery when compared to severely obese groups not enrolled in
planned weight-loss intervention was highly effective for weight loss, improved health-related
quality of life, and resolution of major obesity-associated complications measured at 2 years.
INTRODUCTION
Several studies have shown bariatric surgery as a successful long-term treatment for weight-
reduction for people with extreme (class III) obesity, especially when measured 2 years
postoperatively (1–4). More recently, three prospective randomized controlled trials have
compared health outcomes between bariatric surgery and nonsurgical treatment intervention
(5–8). Importantly, none of these trials included gastric bypass procedures, only one study
included exclusively severely obese subjects (6), one study limited participants to the
overweight BMI range (a range that does not now qualify a patient for bariatric surgery) (5,
8), and one study limited BMI to <40 kg/m2 (7). Further, none of these studies included control
groups not enrolled in weight-loss intervention treatment.
Mingrone et al. (6) randomly assigned 79 severely obese patients to biliopancreatic diversion,
a malabsorptive surgery, or a low-calorie diet (~1,200 kcal/day) and followed all subjects for
1 year. O’Brien and Dixon and colleagues (5,8) randomized 80 overweight participants (BMI
30–35 kg/m2) to a program of very-low-calorie diets, pharmacotherapy, and lifestyle change
for 24 months or to placement of an adjustable gastric band. In addition, Dixon et al. (7)
randomized 60 patients recently diagnosed with diabetes (BMI, >30 kg/m2 and <40 kg/m2) to
primarily lifestyle modification (diet and exercise) with very-low-calorie diet and weight-loss
medications prescribed as appropriate or to placement of an adjustable gastric band. The
Swedish Obesity Subjects (SOS) study (4), a prospective nonrandomized intervention trial,
enrolled over 4,000 surgical and nonsurgical severely obese participants from 25 surgical
departments and 480 primary health-care centers (9). In this study, only 13% of the surgical
patients had gastric bypass surgery, while 19% had adjustable or nonadjustable banding, and
the remaining majority, 68%, underwent vertical banded gastroplasty, a procedure that results
in less weight loss than gastric bypass and is now performed on a very limited basis (9). The
nonsurgical control patients received usual care for weight loss at the center where they
registered for the study. Finally, MacDonald et al. studied 232 severely obese patients, all with
type 2 diabetes. In total, 154 had gastric bypass and the remaining 78 did not have bariatric
surgery due to personal preference or because their health insurance would not cover the
procedure. Control patients received usual care during the follow-up period.
In view of the rapid increase in bariatric surgery (1,10–12), with Roux-en-Y gastric bypass
representing the greater majority of these surgeries in the United States, and in response to the
limited data comparing bariatric surgery to nonsurgical treatment (1), this study was
undertaken. This research represents the only study to date that has exclusively included Roux-
en-Y patients not limited by a specific disease (i.e., diabetes) and that has included comparative
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groups not enrolled in a specific, nonsurgical weight-loss treatment program. Using this design,
the primary hypothesis was to determine health outcomes following gastric bypass surgery in
comparison to severely obese subjects, seeking and not seeking gastric bypass surgery. The
unique inclusion of the two comparative groups provided the opportunity to test what happens
to the health status of severely obese individuals if they are left to their own devices regarding




A total of 1,156 participants comprised the three study groups (Table 1). Two groups included
patients seeking gastric bypass surgery from a partnership of three bariatric surgeons in Utah.
The surgical group (N = 420) underwent gastric bypass surgery while the first comparative
group (N = 415) sought but did not have surgery, primarily as a result of denial of insurance
coverage, and in a few cases due to personal preference. The second comparative group was
population-based, consisting of severely obese participants who were not seeking bariatric
surgery (N = 321). These participants were recruited from the Utah Health Family Tree program
based in high schools (13,14) a database representing over 1 million first-degree relatives from
151,188 families (15). These families had previously given consent for future contact in regard
to research activities. From this database, there were 16,482 individuals who had reported being
at least 100 pounds overweight. These potential severely obese individuals were contacted by
telephone to determine whether (i) they were severely obese (BMI ≥ 35 kg/m2), (ii) they had
not had bariatric surgery, and (iii) they were willing to participate in this study. Exclusion
criteria for all study participants included: previous gastric surgery for weight loss; gastric or
duodenal ulcers in the previous 6 months; active cancer within the past 5 years (except for
nonmelanoma skin cancer); myocardial infarction in the previous 6 months; and history of
alcohol or narcotic abuse.
Of note, gastric bypass patients seeking surgery quite often face an extended application
process of many months before hearing whether or not their surgery is approved, denied or put
on hold pending more clinical data. This situation, coupled with the time-line set forth for this
study, compelled us to recruit all patients visiting the surgical center seeking information about
gastric bypass. Often, subjects expressed willingness to participate in the study before they
knew whether or not health insurance would cover surgical costs. Therefore, many patients
agreed to be in our study, participated in the initial testing and were categorized as “pending-
surgery” subjects. Once the participant found out surgery approval status, they were further
classified as “surgery group” or “seeking surgery but did not have surgery group” (see Figure
1). The primary factor determining group assignment (surgery or seeking surgery but did not
have surgery) was whether or not the insurance company would cover the procedure.
The study protocol was approved by the University of Utah Institutional Review Board, and
signed consent was obtained from all participants.
Surgery technique and study protocol
The surgical group underwent either open or laparoscopic Roux-en-Y gastric bypass, by one
of three surgeons, performed as previously described (16,17). Participants of all three groups
underwent a baseline evaluation, which was performed in the surgical group before surgery.
For most participants (Table 1) the baseline evaluation was performed in the University of
Utah General Clinical Research Center (GCRC) during an overnight stay in which they
completed a series of standardized tests and questionnaires as described elsewhere (18). For
the remaining participants (Table 1) baseline data were obtained in our outpatient clinic where
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identical questionnaires but an abbreviated clinical protocol were administered (18). Subjects
visiting the clinic did so if they preferred not to stay overnight in the GCRC or if the GCRC
was already full for that evening.
All participants were invited to return to the GCRC or our clinic for a 2-year follow-up exam.
For subjects who had moved out of state or who chose not to return, telephone contact was
attempted to obtain self-reported medical endpoint data. Also, release of medical information
forms were mailed to them to attempt to obtain medical records from their primary care
physician or bariatric surgeon to ascertain information on study endpoints. As previously
described (18), coronary heart disease was defined as a myocardial infarction, coronary bypass
surgery, or percutaneous transluminal coronary angioplasty. Hypertension was defined as a
blood pressure of ≥140/90 mm Hg (average of three measurements sitting) or use of
antihypertensive medications. Diabetes was defined as a fasting glucose level of ≥126 mg/dl
or use of antidiabetic medication. Dyslipidemia was defined as low-density lipoprotein-
cholesterol ≥160 mg/dl, high-density lipoprotein-cholesterol <40 mg/dl, or triglycerides ≥200
mg/dl, or use of lipid-lowering medication. In addition to these outcome variables, in all
subjects seen in the GCRC we also obtained a resting metabolic rate (RMR) (indirect
calorimetry), measured the time required to reach 80% of maximal calculated heart rate using
a modified Bruce treadmill protocol, and performed overnight sleep studies to obtain the apnea/
hypopnea index, percent of oxygen saturation readings <90%, and average night-time oxygen
saturation (18).
Due to variation in measurement technique, we specifically describe methods used for
measurement of RMR and body fat. The RMR was measured in the GCRC before the subject
getting out of bed the morning after an overnight stay and 12-h fast. RMR was measured with
open circuit indirect calorimetry using a portable metabolic cart (TrueMax 2400; Parvo Medics,
Salt Lake City, UT) and a plastic ventilated hood. Before data collection, the metabolic system
was calibrated with standard gases of known concentration and participants were familiarized
with the ventilation hood. Participants were asked to remain motionless and not to sleep during
the procedure. Once steady state was obtained, the test was continued for at least 10 min.
Percent body fat was calculated from measurement of resistance and reactance to an electrical
current using bioelectrical impedance equipment (RJL Systems Analyzer; Quantum II, Clinton,
MI). Participants were asked to comply with the following criteria before the impedance
analysis: fasting overnight or for a minimum of 4–5 h; no exercise for at least 12-h; no alcohol
for at least 24-h; and balanced hydration. All participants were asked to lie in a supine position
for at least 5 min before the examination.
Statistical methods
To test the main hypothesis that Roux-en-Y gastric bypass surgery reduces adverse effects of
morbid obesity on disease, our primary comparison was between the surgical and the seeking
but did not have surgery groups, because these two groups were most similar at baseline and
this comparison provided the most valid test of surgery effectiveness. Additional comparisons
were performed between the surgical and population comparative groups to infer whether the
risks and benefits of gastric bypass surgery were replicated when a general population sample
of severely obese subjects were used as comparative subjects. A general linear model was used
to regress the continuous biological variables on a categorical variable representing study
group. Covariates included in the model were gender, age, and baseline BMI. For changes from
baseline, the baseline level of the variable being analyzed was also included as a covariate. A
one-degree-of-freedom P value is reported for the comparison of the surgical group with each
of the comparative groups separately. Because there are two multiple comparisons for each
variable, we considered a P value <0.025 as evidence of statistical significance. Only nominal
P values are reported in the text and tables.
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Disease prevalence, incidence, and resolution were analyzed by logistic regression. Resolution
of disease that was present at baseline was defined as normal levels of the variable without
medication. We also tested the hypothesis that the amount of reduction of BMI or waist
circumference 2 years following gastric bypass surgery would correlate with the improvement
in variables of obesity comorbidity such as lipid levels and blood pressure. Partial correlation
coefficients were estimated adjusting for age, gender, baseline BMI, and baseline levels of the
variable being analyzed, using only gastric bypass subjects who were not on medications for
the variable being analyzed at either exam. Subjects were excluded from analysis of change if
follow-up measurements were not available. All analyses of change were performed both with
and without subjects from the two comparative groups who went on to have bariatric surgery
following baseline testing and before testing at 2-year follow-up. Because the results of these
analyses showed minimal differences in effect size and significance when including subjects
who went on to have bariatric surgery following baseline testing, these subjects were not
included in the reported results.
Results
Baseline results
At baseline, the surgical group was generally well-matched for age, sex, and anthropometric
measurements with the seeking but did not have surgery comparative group (Table 2). The
surgical group compared with the population comparative group was significantly younger,
had greater weight, BMI, percent body fat, and waist circumference (all P < 0.001 or <0.0001).
Although there were minor differences in certain baseline clinical measurements (Table 2),
there were no differences in prevalence of baseline endpoints (i.e., diabetes, hypertension, and
dyslipidemia) between the surgical and population-based comparative group. Prevalence of
disease also did not differ between the surgical group and the comparative group who sought
surgery but did not have surgery.
Follow-up results
Table 1 includes follow-up participation results for each exam by group and the type of exam
(GCRC, clinic, telephone contact for disease endpoints and body weight, and clinic data
obtained from physician’s office). Follow-up time was 2.3 years for each group. There were
four subjects who died during the follow-up period. From the two comparative groups, 68
subjects went on to have bariatric surgery (67 had gastric bypass and 1 had adjustable lap
banding) following baseline but before their follow-up exam. All but two of these participants
returned for the 2-year follow-up testing. At the 2-year follow-up, participants not returning
for the overnight GCRC or cardiovascular genetics clinic visit were phoned to obtain medical
endpoints information as well as self-reported body weight over the telephone and to arrange
for obtaining medical information from their primary care physicians. Of participants eligible
for follow-up (N = 1,156), the total percentage of participants who were followed-up at the
GCRC, cardiovascular genetics clinic, or by telephone for medical endpoint collection and
physician-based medical records was 96, 93, and 98% of the surgery group, seeking surgery
but did not have surgery comparative group, and the population-based comparative group,
respectively. We were unable to contact only 3, 6, and 1% of the three groups. The number of
participants who absolutely refused to visit with us further about follow-up was only 4, 1, and
1 participants of the surgery, seeking surgery but did not have surgery, and population
comparative groups, respectively. Of the two deaths in the surgical group, neither occurred
perioperatively. Of the two deaths in the comparative groups, one subject went on to have
bariatric surgery and died ~11 months following their surgery.
Baseline clinical measurements did not differ significantly between subjects who returned for
follow-up at the GCRC or at our clinic compared with those who did not complete a follow-
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up examination, except for lower percent body fat (P = 0.04), better short form (SF-36) health
survey mental component score (P = 0.01), and better impact of weight quality of life–lite (P
= 0.04) in those who returned.
Table 3 shows baseline and 2-year change results of subjects who had both baseline and follow-
up exams, were not receiving medications (at either exam) that could influence the variable
being analyzed, and who did not participate in bariatric surgery following baseline and before
2-year follow-up testing if they were in a comparative group. The improvements were highly
significant for all major study variables for the gastric bypass surgery group when compared
with the seeking but did not have surgery comparative subjects or the population-based
comparative subjects (Table 3; P < 0.0001 for all variables except diastolic blood pressure and
the SF-35 mental component score, which were significant at P < 0.01). When participants on
medications were included in the 2-year change analysis, the significance of the improvements
in the surgery group compared to the two comparative groups remained the same as the above
reported results without medication with the exception of diastolic blood pressure P < 0.01
rather than P < 0.0001 for surgery compared to population-based comparative subjects.
Table 4 includes the association of change in BMI or waist circumference with change in
quantitative biological measures and psychological inventories (impact of weight quality of
life–lite and SF-36) among the subset of gastric bypass subjects who were unmedicated at both
exams for that clinical variable. BMI reduction correlated significantly with changes in all
variables, except diastolic blood pressure and the mental component of the SF-36
questionnaire. Waist circumference reductions were generally weaker predictors of most
variable changes than were BMI reductions.
Table 5 shows the baseline disease endpoint prevalence and the change in disease status
(incidence and resolution) during the 2-year follow-up period. There were no significant
differences in disease prevalence between the surgical and comparative groups. The surgical
group experienced significantly lower rates of incident disease and greater disease resolution
as compared with each comparative group. Resolution of diabetes occurred in about 80% of
the surgical group, and hypertension and dyslipidemia resolved in ~40–50% of surgical patients
while <1–14% not receiving surgery had resolution of these problems. There were no
significant differences in incidence of cardiovascular events among the three groups; however,
the number of patients with heart disease was small, given the relatively short, 2-year follow-
up period and the relatively young age of the subjects.
DISCUSSION
The prevalence of severe obesity has risen sharply in the past decade and has shown an ever-
increasing economic cost and disease toll in the United States (12). Due to the poor success
rate of medical treatments for severe obesity, bariatric surgery is increasingly used to treat this
disorder and its many comorbidities (10–12,19,20). In fact, the frequency of bariatric surgery
increased sevenfold (from 3.5 to 24.0 per 100,000 population) between 1996 and 2002 (10),
and an estimated 170,000 bariatric surgeries were performed in the United States in 2005
(11,12). The largest portion of this increase was in gastric bypass procedures (12,21). Although
analyzing bariatric surgery outcome data has certain limitations (1), bariatric surgery has been
shown to be an effective treatment for obesity-related comorbidities in individuals who are
severely obese (2–4). In addition, two large studies have recently shown a reduction in total
mortality following bariatric surgery of about one-third (9,22). However, despite the sharp rise
in bariatric surgery and the reported improvement in health outcomes following surgery,
limited research comparing currently employed bariatric surgical procedures to nonsurgical
weight-loss treatments has been reported (1).
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This study represents the first prospective study to exclusively follow gastric bypass patients
whose study inclusion was not limited by disease (i.e., diabetes) and which included for
comparison two nonsurgical severely obese groups, who did not have a planned nonsurgical
weight-loss intervention. Following baseline testing, the nonsurgical subjects were free to
decide whether or not to pursue weight-loss treatment on their own volition. After 2-year
follow-up, surgical patients had significantly greater weight loss, lower incidence and greater
resolution of major obesity-related comorbidity and improved levels of health-related quality
of life compared with the two comparative groups.
In particular, degree of obesity, blood pressure, lipids, glucose, and insulin levels, sleep apnea,
RMR, aerobic capacity, and health-related quality of life all improved significantly after
surgery compared to comparative subjects. These improvements were associated with
resolution of ~80% of diabetes, 40% of hypertension, and 50% of dyslipidemia. High-density
lipoprotein-cholesterol increased by an average of 20% (9.0 mg/dl) in the surgery group, a
greater increase than can be obtained with all but the most aggressive multidrug regimens. This
change in high-density lipoprotein alone would predict about a 20% reduction in cardiovascular
disease risk. Although, the major risk factors for cardiovascular disease were markedly
improved following surgery, the numbers of cardiovascular and cancer events were too small
to evaluate the effectiveness of surgery in reducing such events. In addition to greater disease
resolution, incidence of new hypertension, diabetes, and dyslipidemia was significantly lower
in the postsurgical subjects compared with nonsurgical participants. Furthermore, the amount
of weight lost among surgical patients was significantly associated with the degree of
improvement in most biological measures.
The analysis presented in Table 3 was repeated including all medicated subjects while adjusting
for variable-specific medication use at baseline and at follow-up exams (e.g., adjustment for
diabetes medication use when analyzing glucose, HbA1c, and insulin). Inclusion of medicated
subjects resulted in only minor differences in means and no differences in significance levels,
except for less significance for diastolic blood pressure change in the surgery vs. comparative
subjects not seeking surgery. When those participants from the two comparative groups who
went on to have bariatric surgery after the initial visit were included within the analyses, the
mean values of measures listed in Table 3 changed, but all parameters remained significantly
improved for the surgery group compared to the comparative groups. Although virtually all
study variables improved following surgery, not all risks associated with gastric bypass surgery
were evaluated. In particular, osteoporosis could not be assessed at baseline using dual-energy
X-ray absorptiometry scans due to equipment-related weight restrictions. Also, anemia and
micronutrient deficiency were not assessed.
The degree of postsurgical weight loss by BMI predicted improvements in all clinical variables
(Table 4) except diastolic blood pressure and the mental component of the SF-36, despite the
fact that diastolic blood pressure and the SF-36 score improved in the surgery group. The degree
of post-surgical weight loss by waist circumference also predicted improvement in most
clinical variables. Although studies have shown that diabetes and abnormal glucose, insulin,
HbA1c, and homeostasis model assessment of insulin resistance resolve very early after
surgery, even before observable weight loss (23,24), improvements in these variables at 2 years
still correlated strongly with amount of weight lost at that time point.
Recent review articles and large meta-analyses have focused on bariatric surgery outcomes,
such as cardiovascular disease and diabetes (1–3,25). Data from these reports suggest that
bariatric surgery, especially gastric bypass surgery (1,26), is the most effective treatment for
severely obese patients, at least with regard to short-term weight loss. However, there are key
limitations in the information available from these prior studies. In a recent review, Kushner
and Noble (1) identified significant methodological concerns including inconsistencies in
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surgical technique, definitions, and ascertainment of outcome variables, and incompleteness
in follow-up (1). In addition, very few bariatric surgery studies have included non-surgical
comparative groups.
Two recent randomized control trials of bariatric surgery have demonstrated that bariatric
surgery is far more effective than nonsurgical dietary treatment for the severely obese
population (5,6). In a study by Mingrone et al., obese subjects (n = 79) were randomly assigned
to a low-calorie diet (~1,200 cal) or biliopancreatic surgery. After 1-year follow-up, the women
and men undergoing biliopancreatic surgery lost on average 28 and 34% of their initial weight,
respectively, while the average initial weight loss with diet alone was 5.8% for women and
6.2% for men (6). More recently, O’Brien et al. randomly assigned patients (n = 80) with mild
to moderate obesity (BMI = 30–35 kg/m2) to either a very-low-calorie diet that included
pharmacotherapy and lifestyle change or to surgery for placement of an adjustable gastric band
(5). After 2 years, the surgery group lost an average of 21.6% initial weight compared with an
average weight loss of 5.5% in the nonsurgical group.
The ongoing SOS study included a nonsurgical control group closely matched to bariatric
surgical patients (27). After 10-year follow-up, the average initial weight loss among the
surgical group was 23.4% compared to an increase of 0.1% in the controls (4). However, only
13% of the cases had a gastric bypass procedure. Interestingly, long-term (10 years) results in
the SOS study differed according to surgical procedure type, with gastric banding providing
13.2 ± 13% weight loss, vertical banded gastroplasty 16.5 ± 11%, and gastric bypass 25 ± 11%
(4). In addition, type of surgical procedure demonstrated greater long-term (10 years)
reductions in blood pressure for gastric bypass compared with other surgery types. Changes in
systolic blood pressure in the gastric banding, vertical banded, and gastric bypass surgery
groups were 2.1, 0.4, and −4.7 mm Hg, respectively, and changes in diastolic pressure were
−1.4, −2.5, and −10.4 mm Hg, respectively. Given the more favorable blood pressure outcomes
with gastric bypass, additional long-term research with this procedure is warranted, especially
with broader clinical and outcome measurements, such as those performed in this study.
Our recruitment of two comparative groups allowed us to explore additional questions. Before
surgical intervention, the two surgery-seeking groups were very comparable despite minor
differences in weight (but not BMI), glucose, HbA1c, and high-density lipoprotein-cholesterol.
The comparability of these two groups facilitated direct testing of the effectiveness of gastric
bypass surgery itself in subjects seeking bariatric surgery and with similar health and obesity.
The population-based severely obese comparative subjects who were not seeking weight-loss
surgery group, allowed for comparisons of characteristics of severely obese subjects in the
general population with surgical patients potentially self-selected for significant comorbidities
and other conditions associated with seeking surgery. The population comparative group was
older and had lower BMI compared to the two seeking gastric bypass surgery groups, although
disease prevalence for diabetes, hypertension, and dyslipidemia was not different between the
three groups. Consistent with prior studies (28,29), the health-related quality of life was higher
in population comparative subjects than the other seeking surgery groups, even after adjustment
for age, gender, and BMI. This finding may have suggested that the population-based
comparative subjects were more content with their current state of obesity and perhaps felt
they were healthier. Even though the population-based comparative group did not exactly
match the gastric bypass group, the improvements in the surgical group were far greater than
the baseline differences, and the 2-year follow-up means were much better in absolute terms
than the population-based comparative group. Finally, differences in age and BMI shown at
baseline between the three groups were readily controlled for in multivariate analysis and did
not make a significant impact upon the major clinical changes that occurred in the surgical
group compared to the two comparative groups, and therefore did not affect the validity of the
results. For every parameter, the changes from baseline to follow-up were very large in the
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surgical group (P < 0.0001) in relation to the two comparative groups. The exception to this
finding was a less significant difference (P < 0.01) in diastolic blood pressure and SF-36 mental
component score between the surgical and the comparative group who were not seeking
surgery. Similar clinical benefits using two different comparative groups demonstrate how
robust the study is to differences in makeup of the comparative groups. We believe that the
use of multiple comparative groups is a unique strength of the study.
A recognized limitation of the Utah Obesity Study is that it is not a randomized comparison
of gastric bypass surgery to nonsurgery. However, significant potential barriers to
randomization studies of bariatric surgery have been identified (30–32). Due to differences in
safety and quality-of-life outcomes, randomizing severely obese patients to a nonmedical
treatment arm for long-term follow-up may be “inappropriate” (31), because of the high
mortality risks associated with untreated severe obesity. A further cited barrier includes the
likely unwillingness for patients seeking bariatric surgery to be randomized. These patients
may contend that their entire life has been spent participating in the “nonintervention
arm” (30).
Another potential limitation of this study is that all gastric bypass surgical patients and patients
seeking but not having surgery were recruited from a single high-volume surgical practice of
three surgeons, potentially interfering with the opportunity to generalize the findings to other
locals. Short-term complication rates and even long-term efficacy may differ by procedure and
by subtle variance in surgical technique and other factors between surgeons and surgical
centers. The three surgeons who performed all the operations used the same procedure (Roux-
en-Y gastric bypass) by approximately the same method. Utilizing a single, very experienced
center removes potential differences between centers, provides an excellent test of the
effectiveness of the surgery itself and enhances the validity of the results. Due to improved
patient outcome associated with patient surgery volume (33), bariatric centers are now required
to perform a certain number of specific bariatric surgeries (i.e., ≥100 per year) to qualify as a
center of excellence. The Utah Surgical Center, having performed over 13,000 gastric bypass
procedures, exemplifies this center of excellence requirement. In addition, the mortality in our
surgical group was very low (0.5% at 2 years) supporting the findings that high-surgical volume
strongly reduces short-term mortality (33).
We believe that the size of the study and strength of the findings suggest that results will be
generalizable to a mostly white, female, premenopausal population—the very population
which most commonly seeks this treatment approach in the United States. Lack of sufficient
minority patients participating in this study represents a limitation. The large SOS (4) and the
randomized trials performed in Australia (5,7,8) appear also to be limited by minority
representation. Another limitation of this report is that it provides only intermediate, 2-year
follow-up data.
In summary, despite these limitations, this unique comparative cohort study demonstrates that
gastric bypass surgery, when compared to severely obese subjects not enrolled in structured
nonsurgical weight loss treatment, effectively improves major risk factors for cardiovascular
disease 2 years after surgery. Improvements include dramatically reduced obesity, increased
health-related quality of life, and improvements in other weight-related clinical health
outcomes. Further, at 2-year follow-up, gastric bypass was shown to significantly lower rates
of incident disease and result in greater disease resolution for diabetes, hypertension, and
dyslipidemia.
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Recruitment scheme for gastric bypass surgical patients and patients seeking gastric bypass
but did not have gastric bypass surgery. *In a few instances, patients chose not to have gastric
bypass surgery.
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Table 1










 GCRC, N 307 285 282
 Clinic, N 113 129 39
 Total, N 420 415 321
Follow-up participation
 GCRC or CVG clinic or medical chart abstraction or
Disease Endpoints Questionnaire
402 (96%) 386 (93%) 315 (98%)
 Only GCRC, N 220 173 225
 Only CVG clinic, N 98 97 54
 Only medical chart abstraction or Disease Endpoints
Questionnaire, N
84 116 36
 Comparative subjects going on to have GBP surgery NA 56 12
 Refused follow-up participation 4 1 1
 Lost-to-follow-upa 12 26 4
 Deaths 2 2 0
GCRC, general clinical research center; CVG, cardiovascular genetics; GBP, gastric bypass; NA, not applicable.
a
Represents participants who at the time of follow-up could not be found.













Adams et al. Page 14
Table 2
Baseline mean and s.e. of study variables
Study variables
Gastric bypass patients (N
= 420)
Comparative group: seeking
but did not have bypass
surgery (N = 415)
Comparative group: not
seeking bariatric surgery (N =
321)
Age, years (1,156) 43.4 (0.61) 43.6 (0.62) 49.4 (0.65)****
Sex, % female (1,156) 83.8 85.1 76.0
Weight, kg (1,156) 144.0 (1.24) 140.3 (1.26)* 133.2 (1.37)****
BMI, kg/m2 (1,156) 47.7 (0.41) 46.8 (0.41) 44.3 (0.45)****
Waist circumference, cm (1,155) 139.4 (0.92) 138.4 (0.93) 133.7 (1.02)****
Percent body fat, % (1,141) 45.7 (0.24) 45.4 (0.24) 44.6 (0.26)***
Systolic blood pressure, mm Hg (1,146) 129.3 (0.97) 128.9 (0.97) 128.8 (1.06)
Diastolic blood pressure, mm Hg (1,146) 73.5 (0.59) 73.7 (0.59) 73.1 (0.65)
Resting heart rate, bpm (1,140) 72.8 (0.84) 73.5 (0.84) 73.9 (0.92)
Glucose, mg/dl (1,152) 104.1 (1.92) 109.6 (1.93)* 107.5 (2.10)
Insulin, μU/ml (1,150) 19.8 (0.82) 18.6 (0.83) 15.1 (0.90)****
HOMA-IR (1,148) 5.3 (0.24) 5.1 (0.24) 4.1 (0.26)***
HbA1c, % (929) 5.9 (0.07) 6.1 (0.07)* 6.0 (0.07)
Total cholesterol, mg/dl (1,154) 186.5 (2.01) 182.0 (2.02) 185.1 (2.20)
LDL-cholesterol (measured), mg/dl (1,154) 107.1 (1.52) 104.6 (1.53) 108.1 (1.67)
HDL-cholesterol, mg/dl (1,154) 44.5 (0.59) 42.1 (0.59)** 43.8 (0.64)
VLDL-cholesterol, mg/dl (1,154) 36.1 (1.23) 37.0 (1.24) 34.1 (1.35)
Triglycerides, mg/dl (1,154) 194.7 (7.51) 201.4 (7.58) 185.6 (8.24)
IWQOL–Lite total score (1,057) 65.7 (1.05) 68.5 (1.05) 87.9 (1.14)****
SF-36, Physical component score (1,118) 35.9 (0.34) 36.2 (0.34) 40.0 (0.37)****
SF-36, Mental component score (1,118) 41.3 (0.38) 41.4 (0.38) 44.1 (0.41)****
Apnea/hypopnea index, per h (705) 27.0 (1.56) 27.0 (1.55) 27.1 (1.55)
% Sleep time SpO2 <90%, sin−1, % (705) 0.3159 (0.0229) 0.3143 (0.0233) 0.3189 (0.0227)
Average night-time SpO2, % O2 (705) 90.74 (0.23) 90.74 (0.23) 90.69 (0.22)
Treadmill time, s (782) 631 (15.00) 602 (15.18) 611 (15.36)
RMR, kcal/day (851) 2,391 (31.83) 2,393 (33.09) 2,274 (32.28)**
Weight, BMI, and % fat adjusted for age and gender only; age adjusted for gender only. All other variables adjusted for age, gender, and BMI.
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IWQOL–Lite, impact of weight quality of life–lite;








P < 0.0001 vs. surgical cases.
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Table 4
Association of 2-year change in physiologic measurements and psychological assessments with change in BMI
or waist circumference for surgical group subjects




correlation coefficienta P value
Waist circumference (315) 0.56 <0.0001 — —
Percent body fat (311) 0.76 <0.0001 0.54 <0.0001
Systolic blood pressure (212) 0.26 0.078 0.14 0.037
Diastolic blood pressure (212) 0.06 0.35 0.10 0.15
Resting heart rate (209) 0.19 0.008 0.15 0.03
Glucose (265) 0.24 0.0001 0.15 0.015
Insulin (265) 0.31 <0.0001 0.25 <0.0001
HOMA-IR (259) 0.34 <0.0001 0.26 <0.0001
HbA1c (183) 0.27 0.0002 0.89 0.23
Total cholesterol (271) 0.29 <0.0001 0.31 <0.0001
LDL-cholesterol, measured (271) 0.31 <0.0001 0.32 <0.0001
HDL-cholesterol (267) −0.28 <0.0001 −0.30 <0.0001
VLDL-cholesterol measured (267) 0.44 <0.0001 0.44 <0.0001
Triglycerides (271) 0.48 <0.0001 0.45 <0.0001
IWQOL–Lite total score (298) −0.56 <0.0001 −0.45 <0.0001
SF-36, Physical component score (285) −0.14 0.019 −0.19 0.0016
SF-36, Mental component score (285) −0.11 0.08 −0.06 0.30
Apnea/hypopnea index (148) 0.21 0.012 0.13 0.13
% Sleep time SpO2 <90%, sin−1 (%) (148) 0.29 0.0005 0.29 0.0004
Average night-time SpO2 (148) −0.39 <0.0001 −0.37 <0.0001
Treadmill time, s (157) −0.35 <0.0001 −0.45 <0.0001
RMR, kcal/day (225) 0.39 <0.0001 0.39 <0.0001
Analysis limited to only those surgical subjects not taking medications at either baseline or follow-up that affect the variable being analyzed.
HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IWQOL–Lite, impact of weight quality of life–lite;
LDL, low-density lipoprotein; RMR, resting metabolic rate; VLDL, very low-density lipoprotein.
a
Adjusted for age, gender, baseline BMI or waist circumference, and baseline levels of the variable analyzed.
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